Parker Geoffrey M.

Average Profitability
3.22%
Insider Buys Quantity
12
Insider Buys Sum
$1.56M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Parker Geoffrey M.

According to the SEC Form 4 filings, Parker Geoffrey M., being in a position of

  1. CHIEF FINANCIAL OFFICER at Allogene Therapeutics, Inc.,
    оver the last 12 months, has bought 190 shares for $683, and sold 0 shares,
    over all time since 2024-01-30, has bought 190 shares for $683, and sold 0 shares.

The largest purchase of all time was on 2021-12-16 and amounted to 10000 shares of Perrigo Company plc for $368,540.

Biography of Parker Geoffrey M.

No biography is available at this moment.

2024-01-30PurchaseAllogene Therapeutics, Inc.
ALLO
CHIEF FINANCIAL OFFICER
190
0.0001%
$3.60$683-20.83%
2023-06-13PurchasePerrigo Company plc
PRGO
director
10,000
0.0074%
$33.06$330,637-4.62%
2023-03-06PurchasePerrigo Company plc
PRGO
director
5,000
0.0038%
$38.05$190,270-8.74%
2021-12-16PurchasePerrigo Company plc
PRGO
director
10,000
0.0075%
$36.85$368,540+4.8%
2021-03-17PurchasePerrigo Company plc
PRGO
director
5,000
0.0037%
$41.29$206,436+2.17%
2018-11-12PurchasePerrigo Company plc
PRGO
director
3,000
0.0022%
$65.35$196,058-23.91%
2016-12-09PurchaseViracta Therapeutics, Inc.
VIRX
director
594
0.0038%
$3.90$2,318-22.08%
2016-12-08PurchaseViracta Therapeutics, Inc.
VIRX
director
3,146
0.0201%
$3.87$12,159-21.76%
2016-11-21PurchasePerrigo Company plc
PRGO
director
2,500
0.0017%
$88.75$221,875-13.64%
2016-05-26PurchaseViracta Therapeutics, Inc.
VIRX
director
9,500
0.0109%
$0.47$4,455+40.43%
2016-05-25PurchaseViracta Therapeutics, Inc.
VIRX
director
22,505
0.0255%
$0.49$10,933+34.69%
2016-05-24PurchaseViracta Therapeutics, Inc.
VIRX
director
30,000
0.0333%
$0.46$13,881+37.5%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.